Vážený uživateli, je nám líto, ale Váš prohlížeč nepodporuje plné zobrazení webu. Doporučujeme Vám přejít na jeho aktuálnější verzi (MS Edge) nebo na některý z nejčastějších prohlížečů (Chrome, Firefox, Safari).

Turning Point pays $25 million upfront for rights to anti-Claudin18.2 ADC from LaNova

SOTIO Biotech

7/7/2022 | 2 minuty čtení

Vytisknout
Kopírovat odkaz

PARTNERING

Turning Point announced licensing of clinical anti-Claudin18.2 ADC LM-302 from LaNova Medicines

Turning Point Therapeutics has entered into an exclusive license agreement with LaNova Medicines to develop and commercialize LM-302, a novel ADC targeting Claudin18.2, in the US and rest of the world, excluding Greater China and South Korea. Claudin18.2 is a protein expressed in many gastrointestinal cancers, including gastric, gastroesophageal junction and pancreatic cancer. LM-302, which going forward will be identified as TPX-4589, is currently in Phase 1 clinical trials in both the US and China. LaNova will receive an upfront payment of $25 million and will be eligible to receive up to an additional $195 million in development and regulatory milestone payments; in addition, LaNova is eligible to receive commercial sales milestones, and tiered royalties ranging from mid-single digit to mid-teens percentages on net sales. As part of the agreement, both parties agreed to potentially broaden the partnership by collaborating on up to three additional ADC programs. TPX-4589 (LM-302) is a potentially first-in-class anti-Claudin18.2 ADC discovered by LaNova that suppresses cell proliferation of gastric and pancreatic cell lines with nanomolar potency in preclinical models. It also has demonstrated efficacy in gastric and pancreatic cancer xenograft models.

Gilead and Dragonfly announced collaboration to develop NK cell engagers

Gilead and Dragonfly Therapeutics announced a collaboration designed to advance a number of Dragonfly's novel NK cell engager-based immunotherapies for oncology and inflammation indications. Gilead will receive an exclusive, worldwide license from Dragonfly for the 5T4-targeting investigational immunotherapy program, DF7001. The agreement also grants Gilead options, after the completion of certain preclinical activities, to license exclusive, worldwide rights to develop and commercialize additional NK cell engager programs using the Dragonfly Tri-specific NK Engager (TriNKET) platform. DF7001 is a TriNKET designed to activate and direct NK and cytotoxic T cell killing against cancer cells. It has the potential to trigger the killing of 5T4+ expressing cells, including tumor cells, cancer-associated fibroblasts and cancer stem cells. The program is on track for filing an IND application in the first half of 2023.

Overview of transactions in oncology (values in m$)

Source

Partner

Product

Stage

Rights

Value

UF

MS

Cullinan Pearl

Taiho Pharma

Acquisition of company developing CLN-081 small molecules EGFR exon20 inhibitor against NSCLC

Ph 1/2

NV

405

275

130

Myovant Sciences

Accord Healthcare

License to Orgovyx relugolix, an GNRHR antagonist approved for prostate cancer

Market

EU,UK, CH,TU

141

50

91

NiKang Therapeutics

Hansoh Pharma

License to NKT2152 small molecule endothelial PAS domain containing protein 1 inhibitor against RCC

Ph 1/2

CN,HK, TW,MC

218

15

203

LaNova Medicines

Turning Point Therapeutics

License to LM-302, and ADC targeting Claudin18.2 developed against gastro-intestinal stromal tumors

Ph 1

Ex-CN, HK,TW, MC,KR

220

25

195

BridgeBio Pharma

BMS

License to BBP-398 small molecule SHP-2 inhibitor against RTK cancers

Ph 1

WW

NA

30

NA

Evotec

BMS

License to EVO panOmics and EVO panHunter platforms to develop precision medicines

Res

NA

5 200

200

5 000

Kelun Pharma

Merck & Co.

License to an undisclosed cancer treating drug

NA

NA

1 407

47

1 360

Amphista Therapeutics

Merck KGaA

License to Eclipsys, a targeted protein degradation platform to develop novel small molecules against cancer

Res

WW

1 044

44

1 000

Dragonfly Therapeutics

Gilead Sciences

License to DF7001 tri-specific NK engager targeting oncofetal antigen 5T4 against caner indications

Precl

WW

NA

300

NA

NASDAQ Initial Public Offerings (IPOs) in oncology

None

Sdílet na sociálních sítích

Sdílet na sociálních sítích

Vytisknout

Kopírovat odkaz